Metopimazine

Study	Exclusion reasons	Rmk	Reference
Paradis, 1967	inadequate or absent control group	EXCLUDED: all pregnant women were treated with metopimazine. No adequate control group.	Paradis Laval Med 1967; 38:901-7
Benevent, 2019	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Atropinic drugs analyzed as a whole without distinction between treatments.	Benevent Fundam Clin Pharmacol 2019; 33:314-326 10.1111/fcp.12428
Beau, 2016	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Atropinic drugs analyzed as a whole without distinction between treatments.	Beau Br J Clin Pharmacol 2016; 82:478-86 10.1111/bcp.12978
Potchoo, 2009	pattern of exposure	EXCLUDED: study on prescription pattern, safety outcomes provided as a whole (without distinction between treatment). A table described 4 neonatal abnormalities, but no clear control group nor total number of exposed pregnant women.	Potchoo Eur. J. Clin. Pharmacol. 2009; 65:831-8 10.1007/s00228-009-0644-5
Mikou, 2008	pattern of exposure	EXCLUDED: study on pattern of exposure, without data on safety fetal/neonatal/maternal outcomes.	Mikou Therapie 2008; 63:415-.